Amendment Tool

v1.6 06 December 2021

For office use QC: No

Short project title*:	PhEAST											
IRAS project ID* (or REC reference if no IRAS project ID is available):	304658											
Sponsor amendment reference number*:	NSA_21_23											
Sponsor amendment date* (enter as DD/MM/YY):	12 October 2023											
Briefly summarise in lay language the main changes proposed in this amendment. Explain the purpose of the changes and their significance for the study. If the amendment significantly alters the research design or methodology, or could otherwise affect the scientific value of the study, supporting scientific information should be given (or enclosed separately). Indicate whether or not additional scientific critique has been obtained (note: this field will adapt to the amount of text entered)*:	This amendment co	nsists of the additio	n of three new NHS	S recruiting sites.								
				Specific stu	ıdy							
Project type (select):				Research tissue bank								
				Research database								
Has the study been reviewed by a UKECA-recognised Res Committee (REC) prior to this amendment?:	search Ethics	Y	es		No							
What type of UKECA-recognised Research Ethics Commit			NHS/HSC R	EC								
is applicable? (select):	. ,			Ministry of D	efence (MoDREC							
Is all or part of this amendment being resubmitted to the Re Committee (REC) as a modified amendment (i.e. a subst amendment previously given an unfavourable opinion)?	Y	es	No									
Where is the NHS/HSC Research Ethics Committee (REC) that reviewed	England	Wales	Scotland	Northern Irelan							
the study based?:	, ,	Yes	No	No	No							
Was the study a clinical trial of an investigational medicinal OR does the amendment make it one?:	Y	es	Νο									
Was the study a clinical investigation or other study of a me does the amendment make it one?:	edical device OR	Y	es		No							
Does this clinical investigation or other study of a meo require a Notice of No Objection from MHRA Devices			Yes		No							
Did the study involve the administration of radioactive subs requiring ARSAC review, OR does the amendment introdu		Y	es		No							
Did the study involve the use of research exposures to ioni (not involving the administration of radioactive substances) amendment introduce this?:	Y	es	No									
Did the study have Radiation Assurance OR is Radiation being sought for the first time because of this amendme			Yes		No							
Did the study involve adults lacking capacity OR does the a introduce this?:	Y	es	No									
Did the study involve access to confidential patient informa direct care team without consent OR does the amendment	Y	es	No									
Did the study involve prisoners or young offenders who are supervised by the probation service OR does the amendm this?:	Y	es	No									
Did the study involve children OR does the amendment int	Y	es	No									
Did the study involve NHS/HSC organisations prior to this a	Y	es	No									
Did the study involve non-NHS/HSC organisations OR does the amendment introduce them?:		Y	es		No							
		England	Wales	Scotland	Northern Irelan							
Lead nation for the study:		Yes	No	No	No							
Which nations had participating NHS/HSC organisations pramendment?	rior to this	Yes	Yes	Yes	Yes							
Which nations will have participating NHS/HSC organisatio	1		Yes									

Section 2: Summary of change(s)

Please note: Each change being made as part of the amendment must be entered separately. For example, if an amendment to a clinical trial of an investigational medicinal product (CTIMP) involves an update to the Investigator's Brochure (IB), affecting the Reference Safety Information (RSI) and so the information documents to be given to participants, these should be entered into the Amendment Tool as three separate changes. A list of all possible changes is available on the "Glossary of Amendment Options" tab. To add another change, click the "Add another change" box.

	Change 1								
Area of change (select)*:									
Specific change (select - only available when area of change is selected first)*:	ertaking the same activities as existing sites								
Further information (free text - note that this field will adapt to the amount of text entered): The following sites will be added as recruiting sites in the PhEAST study: 1) Maidstone Darent Valley Hospital, Maidstone & Tunbridge Wells NHS Trust, PI: Helen Day. 2) Darent Valley Hospital, Dartford and Gravesham NHS Trust, PI: Prasanna Aghoram. 3) E Surrey Hospital, Surrey and Sussex Healthcare NHS Trust, PI: Zoe Maylon.									
Applicability:		England	Wales	Scotland	Northern Ireland				
Where are the participating NHS/HSC organisations locate by this change?*:	Yes	No	No	No					
Will all participating NHS/HSC organisations be affected by some? (please note that this answer may affect the categ change):	4	All	Some						
				Add anot	her change				

Section 3: Declaration(s) and lock for submission Declaration by the Sponsor or authorised delegate • I confirm that the Sponsor takes responsibility for the completed amendment tool • I confirm that I have been formally authorised by the Sponsor to complete the amendment tool on their behalf Name [first name and surname]*: Alison Thorpe Email address*: sponsor@nottingham.ac.uk Lock for submission Please note: This button will only become available when all mandatory (*) fields have been completed. When the button is available, clicking it will generate a locked PDF copy of the completed amendment tool which must be included in the amendment submission. Please ensure that the amendment

Lock for submission

After locking the tool, proceed to submit the amendment online. The "Submission Guidance" tab provides further information about the next steps for the amendment.

Section 4: Review bodies for the amendment

tool is completed correctly before locking it for submission.

Please note: This section is for information only. Details in this section will complete automatically based on the options selected in Sections 1 and 2.

		Review bodies																	
	UK wide:					Eng	England and Wales:			Scotland:			Northern Ireland:						
	REC	Competent Authority MHRA - Medicines	Competent Authority MHRA - Devices	ARSAC	Radiation Assurance	UKSW Governance	REC (MCA)	CAG	SddMH	HRA and HCRW Approval	REC (AWIA)	рврр	SPS (RAEC)	National coordinating function	HSC REC	HSC Data Guardians	Prisons	National coordinating function	Category
Change 1:						(Y)				(Y)									New site
Overall reviews for the amendm	ent:																		
Full review:						Ν				Ν									
Notification only:						Y				Y									
Overall amendment type:	No	Non-substantial, no study-wide review required																	
Overall Category:	Ne	ew site																	